Biotechnology company Moderna (NASDAQ:MRNA) in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The ...

RNA-1083 vaccine is noninferior and induces higher immune responses than recommended influenza and COVID-19 vaccines.

MM+M Women of Distinction honoree, announced Monday morning that she has joined Medtronic Diabetes as its chief marketing ...

We recently published a list of Billionaire David E. Shaw’s 10 Small-Cap Stock Picks with Huge Upside Potential. In this ...

A combination messenger RNA vaccine against COVID-19 and seasonal influenza stacked up well against currently recommended vaccines in a phase 3 trial, according to findings published in JAMA.

A new vaccine developed by Moderna aims to protect against both flu and COVID-19 with just one shot. Early studies suggest ...

Moderna has tested its first flu and COVID combination vaccine shot. Dr. Bill Hartman from UW Health joined FOX6 to talk ...

(Gray News) - A combination shot for flu and COVID-19 using messenger RNA-generated antibodies in a study, but U.S.

Senior leaders at the FDA began pushing Moderna and Pfizer to file for full, formal approval of their COVID vaccines for ...

Moderna also hopes that combining the shots will help improve vaccine rates. Poland, however, is not sure people will like ...

The trial, which involved more than 8,000 adults 50 and older, found that antibody levels generated by the new vaccine were about 20% to 40% higher than getting the shots apart, with the exception of ...

Moderna’s new combination vaccine for seasonal influenza and COVID-19 has outperformed current standard vaccines in a large phase 3 clinical trial, showing stronger immune responses to both viruses in ...